版本:
中国

Celgene's multiple sclerosis drug succeeds in late-stage trial

May 22 Celgene Corp said its oral drug to treat relapsing multiple sclerosis met the main goal of reducing annualized relapse rate, when compared to Biogen Inc's Avonex, in a second late-stage study.

The drug, ozanimod, succeeded in another late-stage study in February.

Celgene said on Monday it expected to file for U.S. marketing application by the end of this year.

Ozanimod is also being tested for ulcerative colitis and Crohn's disease. (Reporting by Divya Grover in Bengaluru; Editing by Sriraj Kalluvila)

我们的标准: 汤森路透“信任原则

更多 公司新闻(英文)

热门文章

编辑推荐

文章推荐